Suppr超能文献

寨卡病毒 NS5 的结构洞察导致 MTase 抑制剂的发现。

Structural Insight into NS5 of Zika Virus Leading to the Discovery of MTase Inhibitors.

机构信息

Axe Molecular Endocrinology and Nephrology, CHU Research Center and Department of Molecular Medicine, Laval University , Québec City, Québec G1V 4G2, Canada.

Axe Infectious Disease, CHU Research Center and Laval University , Québec City, Québec G1V 4G2, Canada.

出版信息

J Am Chem Soc. 2016 Dec 21;138(50):16212-16215. doi: 10.1021/jacs.6b10399. Epub 2016 Dec 6.

Abstract

Zika virus (ZIKV) is an emerging mosquito-borne virus recently linked to intrauterine growth restriction including abnormal fetal brain development. The recent outbreak of ZIKV reached pandemic level resulting in an alarming public health emergency. At present, there is limited understanding of the infectious mechanism and no approved therapy. Nonstructural protein 5 is essential for capping and replication of viral RNA and comprises a methyltransferase (MTase) and RNA dependent RNA polymerase domain. Here we used molecular modeling to obtain the structure of ZIKV MTase and molecular docking to identify the additional hydrophobic region uniquely conserved in flavivirus MTase that can be used as a druggable site. Subsequently, a virtual screening with a library of 28 341 compounds identified 10 best hits showing decisive contacts with the MTase. In vitro efficacy analysis of these compounds against ZIKV, by plaque reduction assay, has confirmed four of the top scored ligands (Life Chemicals ID: F3043-0013, F0922-0796, F1609-0442, and F1750-0048) having EC50 (50% effective concentration) values of 4.8 ± 2.3, 12.5 ± 7.4, 17.5 ± 8.4, and 17.6 ± 3.1 μM respectively, identifying lead compounds for anti-ZIKV drug development.

摘要

寨卡病毒(ZIKV)是一种新近出现的蚊媒病毒,最近与宫内生长受限有关,包括胎儿大脑发育异常。最近的寨卡病毒爆发已达到大流行水平,构成了令人震惊的公共卫生紧急事件。目前,人们对其感染机制的了解有限,也没有批准的治疗方法。非结构蛋白 5 对于病毒 RNA 的加帽和复制是必需的,它包含一个甲基转移酶(MTase)和 RNA 依赖性 RNA 聚合酶结构域。在这里,我们使用分子建模获得了 ZIKV MTase 的结构,并进行了分子对接,以鉴定在黄病毒 MTase 中独特保守的额外疏水区,该区域可作为可成药的靶点。随后,对包含 28341 个化合物的文库进行虚拟筛选,确定了 10 个最佳命中化合物,它们与 MTase 显示出决定性的接触。通过蚀斑减少测定法对这些化合物针对 ZIKV 的体外疗效分析,已经证实了排名前四的配体(Life Chemicals ID:F3043-0013、F0922-0796、F1609-0442 和 F1750-0048)具有 4.8±2.3、12.5±7.4、17.5±8.4 和 17.6±3.1 μM 的 EC50(50%有效浓度)值,确定了用于抗 ZIKV 药物开发的先导化合物。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验